Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.; Orkin, C.; Cunningham, D.; Pulido, F.; Post, F.A.; De Wit, S.; Lathouwers, E.; Hufkens, V.; Jezorwski, J.; Petrovic, R.; Brown, K.; Van Landuyt, E.; Opsomer, M.; De Wit, S.; Florence, E.; Moutschen, M.; Van Wijngaerden, E.; Vandekerckhove, L.; Vandercam, B.; Brunetta, J.; Conway, B.; Klein, M.; Murphy, D.; Rachlis, A.; Shafran, S.; Walmsley, S.; Ajana, F.; Cotte, L.; Girardy, P.-M.; Katlama, C.; Molina, J.-M.; Poizot-Martin, I.; Raffi, F.; Rey, D.; Reynes, J.; Teicher, E.; Yazdanpanah, Y.; Gasiorowski, J.; Halota, W.; Horban, A.; Piekarska, A.; Witor, A.; Arribas, J.R.; Perez-Valero, I.; Berenguer, J.; Casado, J.; Gatell, J.M.; Gutierrez, F.; Galindo, M.J.; Gutierrez, M.D.M.; Iribarren, J.A.; Knobel, H.; Negredo, E.; Pineda, J.A.; Podzamczer, D.; Sogorb, J.P.; Pulido, F.; Ricart, C.; Rivero, A.; Santos Gil, I.; Blaxhult, A.; Flamholc, L.; Gisslèn, M.; Thalme, A.; Fehr, J.; Rauch, A.; Stoeckle, M.; Clarke, A.; Gazzard, B.G.; Johnson, M.A.; Orkin, C.; Ustianowski, A.; Waters, L.; Bailey, J.; Benson, P.; Bhatti, L.; Brar, I.; Bredeek, U.F.; Brinson, C.; Crofoot, G.; Cunningham, D.; DeJesus, E.; Dietz, C.; Dretler, R.; Eron, J.; Felizarta, F.; Fichtenbaum, C.; Gallant, J.; Gathe, J.; Hagins, D.; Henn, S.; Henry, W.K.; Huhn, G.; Jain, M.; Lucasti, C.; Martorell, C.; McDonald, C.; Mills, A.; Morales-Ramirez, J.; Mounzer, K.; Nahass, R.; Olivet, H.; Osiyemi, O.; Prelutsky, D.; Ramgopal, M.; Rashbaum, B.; Richmond, G.; Ruane, P.; Scarsella, A.; Scribner, A.; Shalit, P.; Shamblaw, D.; Slim, J.; Tashima, K.; Voskuhl, G.; Ward, D.; Wilkin, A.; de Vente, J.

doi:10.1016/J.ANTIVIRAL.2019.104543

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.
Orkin, C.
Cunningham, D.
Pulido, F.
Post, F.A.
De Wit, S.
Lathouwers, E.
Hufkens, V.
Jezorwski, J.
Petrovic, R.
Brown, K.
Van Landuyt, E.
Opsomer, M.
De Wit, S.
Florence, E.
Moutschen, M.
Van Wijngaerden, E.
Vandekerckhove, L.
Vandercam, B.
Brunetta, J.
Conway, B.
Klein, M.
Murphy, D.
Rachlis, A.
Shafran, S.
Walmsley, S.
Ajana, F.
Cotte, L.
Girardy, P.-M.
Katlama, C.
Molina, J.-M.
Poizot-Martin, I.
Raffi, F.
Rey, D.
Reynes, J.
Teicher, E.
Yazdanpanah, Y.
Gasiorowski, J.
Halota, W.
Horban, A.
Piekarska, A.
Witor, A.
Arribas, J.R.
Perez-Valero, I.
Berenguer, J.
Casado, J.
Gatell, J.M.
Gutierrez, F.
Galindo, M.J.
Gutierrez, M.D.M.
Iribarren, J.A.
Knobel, H.
Negredo, E.
Pineda, J.A.
Podzamczer, D.
Sogorb, J.P.
Pulido, F.
Ricart, C.
Rivero, A.
Santos Gil, I.
Blaxhult, A.
Flamholc, L.
Gisslèn, M.
Thalme, A.
Fehr, J.
Rauch, A.
Stoeckle, M.
Clarke, A.
Gazzard, B.G.
Johnson, M.A.
Orkin, C.
Ustianowski, A.
Waters, L.
Bailey, J.
Benson, P.
Bhatti, L.
Brar, I.
Bredeek, U.F.
Brinson, C.
Crofoot, G.
Cunningham, D.
DeJesus, E.
Dietz, C.
Dretler, R.
Eron, J.
Felizarta, F.
Fichtenbaum, C.
Gallant, J.
Gathe, J.
Hagins, D.
Henn, S.
Henry, W.K.
Huhn, G.
Jain, M.
Lucasti, C.
Martorell, C.
McDonald, C.
Mills, A.
Morales-Ramirez, J.
Mounzer, K.
Nahass, R.
Olivet, H.
Osiyemi, O.
Prelutsky, D.
Ramgopal, M.
Rashbaum, B.
Richmond, G.
Ruane, P.
Scarsella, A.
Scribner, A.
Shalit, P.
Shamblaw, D.
Slim, J.
Tashima, K.
Voskuhl, G.
Ward, D.
Wilkin, A.
de Vente, J.
Erakutsi egile guztiak +

Aldizkaria:

Antiviral Research

ISSN: 1872-9096, 0166-3542

Argitalpen urtea: 2019

Alea: 170

Mota: Artikulua

DOI: 10.1016/J.ANTIVIRAL.2019.104543 GOOGLE SCHOLAR Sarbide irekia editor

Datuen iturria: Scopus